Table 3.
Effects of NHF and NIV on respiratory outcomes in NMD patients at night
No treatment (n = 16) | NHF 20 (n = 16) | p1) | NHF 50 (n = 11) | p1) | NIV (n = 16) | p1) | p2) | |
---|---|---|---|---|---|---|---|---|
AHI, /h | 9.5 (0.7–16.5) | 6.8 (2.5–31.2) | - | 20.7 (1.1–28.9) | - | 2.3 (0.0–3.9) | - | n.s.§ |
AI, /h | 1.2 (0.0–13.8) | 4.0 (0.4–21.3) | - | 19.3 (1.1–28.9) | - | 0.2 (0.0–3.1) | - | n.s.§ |
cAI, /h | 0.0 (0.0–0.8) | 0.3 (0.0–6.9) | - | 1.2 (0.0–13.9) | - | 0.0 (0.0–0.9) | - | n.s.§ |
oAI, /h | 0.0 (0.0–5.4) | 1.0 (0.0–8.0) | - | 0.9 (0.0–7.3) | - | 0.0 (0.0–0.0) | - | n.s.§ |
HI, /h | 0.9 (0.0–6.5) | 2.2 (0.4–5.4) | - | 0.0 (0.0–0.6) | - | 0.2 (0.0–1.5) | - | n.s.§ |
ODI, /h | 5.5 (0.7–13.0) | 2.7 (0.8–21.2) | - | 0.9 (0.0–25.4) | - | 1.0 (0.0–1.6) | - | n.s.§ |
Mean SpO2 (%) | 94.1 ± 2.8 | 94.1 ± 4.0 | - | 94.3 ± 3.9 | - | 95.6 ± 2.5 | - | n.s.& |
Minimum SpO2, % | 86.2 ± 6.9 | 85.9 ± 11.2 | - | 86.1 ± 11.4 | - | 84.6 ± 11.2 | - | n.s.& |
t < 90%, min | 1.6 (0.0–17.0) | 1.1 (0.0–5.9) | - | 0.4 (0.0–17.2) | - | 0.3 (0.0–3.5) | - | n.s.§ |
Mean ptcCO2, mmHg | 45.5 ± 4.7 | 44.9 ± 4.2 | n.s. | 43.1 ± 6.5 | n.s. | 39.9 ± 3.5 | 0.007 | 0.063& |
Peak ptcCO2, mmHg | 50.1 ± 6.6 | 50.1 ± 7.9 | n.s | 46.4 ± 6.6 | n.s. | 44.8 ± 2.6 | 0.001 | 0.009& |
Values are based on the actual duration of each intervention (no treatment, NHF20, NHF50, NIV). Values are expressed as mean and standard deviation or median and interquartile range (in brackets). Post hoc tests were not performed when results of multigroup comparisons were non-significant. As an exception, the p value is reported for the post hoc t test comparing mean ptcCO2 between the NIV and “no treatment” period
NHF nasal high flow, NIV non-invasive ventilation, AHI apnoea-hypopnea index, AI apnoea index, cAI central apnea index, oAI obstructive apnoea index, HI hypopnea index, ODI oxygen desaturation index, SpO2 peripheral oxygen saturation, t < 90% duration of oxygen desaturation ≥ 3%, ptcCO2 transcutaneous carbon dioxide tension
1)p values for comparison with baseline values (“no treatment”) using either the paired t test or the Wilcoxon rank-sum test as appropriate
2)p value for comparison between all groups/variables
§Kruskal-Wallis test
&Univariate ANOVA